Computer Simulation Helps Plan Transducer Placement in Glioblastoma
October 13th 2016For patients who are likely to experience contiguous recurrence of glioblastoma, a new computer simulation using tumor treating fields and employing a personalized transducer array, delivered electric field intensities that exceeded therapeutic intensities in 3 different tumor locations. The findings may aid treatment planning when using the NovoTAL System, which optimizes therapeutic delivery in 2 orthogonal directions to the gross tumor volume and proximal peri-tumoral brain zone.
Read More
Minimal Toxicities Reported in Extreme Hypofractionated Comparison Trial in Prostate Cancer
October 10th 2016Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.
Read More
H-RT Reduces Treatment Time by One-Third in Low-Risk Prostate Cancer
October 5th 2016Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.
Read More
Similar Survival Rates Reported Across Treatment Options for Localized Prostate Cancer
September 21st 2016Treatment options for men with localized prostate cancer include active surveillance, radical prostatectomy, or external-beam radiotherapy, but in the Prostate Testing for Cancer and Treatment trial each therapy was associated with a low prostate-specific mortality rate of about 1%.
Read More
QOL in Men Undergoing Monitoring for Prostate Cancer Similar to Men With No Disease
September 19th 2016Men with positive needle biopsy for prostate cancer who underwent active surveillance exhibited no difference in quality-of-life compared with men who had a negative prostate needle biopsy.
Read More
Signature Trial Program Aims for Rapid Delivery of Novel Therapies
August 4th 2016A collection of clinical trials that uses a target-specific and tissue-agnostic algorithm to rapidly match patients to investigational therapies aimed at the tumor's molecular makeup takes the approach that "one trial really does not fit all."
Read More
Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC
July 4th 2016An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.
Read More
Second-Generation AR-Targeting Agent Explored in High-Risk Prostate Cancer
June 15th 2016Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.
Read More
Atezolizumab Effective in First-Line Setting in Bladder Cancer
June 6th 2016Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).
Read More
FDA Approves Radioactive Imaging Agent Axumin in Recurrent Prostate Cancer
May 27th 2016The radioactive imaging agent, fluciclovine F18 (Axumin), was approved by the FDA for use in positron emission tomography scans in men with suspected recurrence of prostate cancer whose prostate-specific antigen levels rise following prior treatment.
Read More
Gene Expression Signature Predicts Hormonal Resistance in Prostate Cancer
May 24th 2016Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.
Read More
ERBB Alteration Linked to Improved PFS With Afatinib in Urothelial Cancer
May 5th 2016Five of 6 patients with metastatic urothelial cancer and at least 1 of 2 genetic alterations demonstrated a marked improvement in 3-month progression free survival of 6.6 months when given afatinib (Gilotrif), compared with patients who lacked these specific genetic abnormalities.
Read More
Acalabrutinib Challenges Ibrutinib in High-Risk CLL Trial
April 22nd 2016Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).
Read More
Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types
March 30th 2016Researchers have designed a recently launched clinical study into entrectinib, a first-in-class inhibitor of tropomyosin receptor kinases, as a basket trial in which the drug can be evaluated simultaneously for activity against three gene alterations and multiple tumor types.
Read More
Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways
March 29th 2016Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.
Read More
Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer
March 22nd 2016Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.
Read More
Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials
March 10th 2016The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).
Read More
Biomarker-Directed Galeterone Explored in Prostate Cancer Trial
February 24th 2016Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.
Read More
FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer
February 23rd 2016The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.
Read More